CONCISE REPORT

The H2 blocker famotidine suppresses progression of ossification of the posterior longitudinal ligament in a mouse model

Yujiro Maeda,1,2 Kenichi Yamamoto,1,2 Akira Yamakawa,2 Hailati Aini,3 Tsuyoshi Takato,1 Ung-il Chung,2,3 Shinsuke Ohba2,3

ABSTRACT

Background: Ossification of the posterior longitudinal ligament (OPLL) of the spine is a common human myelopathy that leads to spinal cord compression. No disease-modifying drug for OPLL has been identified, whereas surgery and conservative management have been established.

Objectives: To evaluate the therapeutic potential of the H2 blocker famotidine for ectopic ossification in the cervical spine in an OPLL mouse model.

Methods: The H2 blocker famotidine was orally administered to Enpp1ttw/ttw mice, a model of OPLL, at either 4 or 15 weeks of age. Radiological and survival rate analyses were performed to assess the effects of famotidine on OPLL-like lesions and mortality in Enpp1ttw/ttw mice.

Results: Oral administration of famotidine suppressed the progression of OPLL-like ectopic ossification and reduced mortality in Enpp1ttw/ttw mice when administration began at 4 weeks of age, early in the development of ossification.

Conclusions: This study points to the use of famotidine as a disease-modifying drug for ectopic ossification of spinal soft tissue, including OPLL.

INTRODUCTION

Ossification of the posterior longitudinal ligament (OPLL) of the spine is a common human myelopathy.1 2 The ossification progresses slowly, but leads to spinal cord compression. OPLL is a multifactorial disease caused by genetic as well as environmental factors, although a number of susceptibility genes has been reported.3 Conservative management is preferred for patients without myelopathy, but surgery is usually necessary for neurological symptoms.4 There is a relatively high incidence of surgical complications in cervical OPLL compared with that in other cervical degenerative diseases.

Complete removal of ossified foci is difficult and leads to postoperative progression and recurrent neurological symptoms.5 Although disease-modifying drugs for OPLL might prevent this, only a few candidates, including bisphosphonate and a P2 purinoceptor Y1 (P2Y1) antagonist, have been proposed.6 There is a need to develop drugs targeting the progression of OPLL.

Cimetidine, a histamine receptor H2 (Hrh2) antagonist (H2 blocker), was reported to improve shoulder calcific tendinitis symptoms.7 We recently identified the inhibitory effect of another H2 blocker, famotidine, on osteogenic differentiation of tendon cells in vitro.8 Oral administration of famotidine also decreased the calcified region in the Achilles tendon of Enpp1ttw/ttw mice,8 which carried a point mutation for the ectonucleotide pyrophosphatase/phosphodiesterase 1 (Enpp1) gene.9 Enpp1 is a susceptibility gene for OPLL.3 10 11 Enpp1ttw/mw mice have been proposed as a model for OPLL.9 Based on these factors, we hypothesised that H2 blockers might negatively affect progression of OPLL as well as tendon calcification.

In this study, we aimed to evaluate the therapeutic potential of famotidine for ectopic ossification in the cervical spine in the Enpp1ttw/mw OPLL model mouse line.

Key messages

▸ Only a few candidates for disease-modifying drugs for OPLL have been proposed.
▸ Oral administration of famotidine suppressed the progression of OPLL-like ectopic ossification in a mouse model.
▸ The finding may reposition H2 blockers, which has been widely used as gastrointestinal agents, for the treatment of intractable OPLL.

To cite: Maeda Y, Yamamoto K, Yamakawa A, et al. The H2 blocker famotidine suppresses progression of ossification of the posterior longitudinal ligament in a mouse model. RMD Open 2015;1:e000068. doi:10.1136/rmdopen-2015-000068

▸ Prepublication history and additional material is available. To view please visit the journal (http://dx.doi.org/10.1136/rmdopen-2015-000068).

YM and KY contributed equally.

Received 12 January 2015
Revised 3 April 2015
Accepted 24 April 2015

For numbered affiliations see end of article.

Correspondence to
Dr Shinsuke Ohba;
ohba@bineng.t.u-tokyo.ac.jp
METHODS

Details are in online supplementary methods. Famotidine was orally administered to Enpp1ttw/ttw mice at either 4 or 15 weeks of age at a dose of 0.667 μg/g/day. Ectopic ossification around the cervical spine was quantitatively analysed using sequential micro-CT. Quantitative data were expressed as mean±SD; statistical significance was evaluated using analysis of variance and Student t test. All experiments were performed in accordance with the protocol approved by the Animal Care and Use Committee of The University of Tokyo (#KA12-5).

RESULTS

Progression of ectopic ossification in cervical spines is suppressed by famotidine administration

To evaluate the effects of H2 blockers on OPLL-like ectopic ossification, famotidine was administered orally to Enpp1ttw/ttw mice. Since ossification becomes evident around 8 weeks of age,11 oral administration of famotidine was started at 4 weeks of age. Each group consisted of four male and four female mice. At 5, 8, 11, 13 and 15 weeks of age, ectopically ossified regions in cervical spines were quantified using reconstructed three-dimensional micro-CT images.

All 16 Enpp1ttw/ttw mice tested exhibited ectopic ossification of the cruciform ligament in the atlanto-occipital area by 8 weeks of age, as previously reported11; the extent of ossification increased throughout the observation period (figures 1A,B and 2). The ectopic ossification was smaller in the famotidine group than in controls (figure 1A). Quantitative analyses revealed that volume and mineral content of calcified ligaments were both significantly smaller in the famotidine group than in controls (figure 1B), but mineral density was not significantly different. Figure 2 shows individual variability of quantitative data in each group; female mice tended to have more severe ectopic ossification than male mice (see online supplementary figure S1).

To gain insights into potential adverse effects of famotidine on bone metabolism, we measured serum calcium levels at 1, 3, 6 and 24 h in WT mice after single-shot famotidine administration (see online supplementary figure S2A), and serum calcium levels and bone mass in Enpp1ttw/ttw mice exposed to 1-month administration (see online supplementary figure S2B and S2C). Neither calcium levels nor bone mass were largely changed by famotidine administration compared with the relevant controls (see online supplementary figure S2A–C).

Survival rates are improved by famotidine in Enpp1ttw/ttw mice

We assessed survival rates in Enpp1ttw/ttw mice with or without famotidine. To examine the effect of famotidine...
on more advanced ectopic ossification in cervical spines, we created another treatment group, with famotidine administered from 15 weeks of age. Thus, we analysed Enpp1ttw/ ttw mice treated with famotidine from 4 weeks of age or controls. X-axes indicate ages of mice. Mineral cont., mineral content; Mineral dens., mineral density.

**DISCUSSION**

Our study results suggest that famotidine can act as a disease-modifying drug for ectopic ossification of spinal soft tissue, potentially repositioning H2 blockers, widely used as gastrointestinal agents, for the treatment of intractable OPLL. We further propose that famotidine may be suitable for preventing recurrence after surgery for OPLL, but not for reversing established lesions, since delayed administration resulted in less improvement in the survival rate in Enpp1ttw/ ttw mice. The gender difference in the reduction of mortality of Enpp1ttw/ ttw mice by famotidine may be attributable to the more advanced ectopic ossification in females than in males. In addition, the distinct penetrance of Enpp1ttw/ ttw phenotypes may underlie the lower survival rate in the group exposed to the delayed administration of famotidine compared with the control group.

Cellular and molecular mechanisms for H2 blockers on OPLL were not considered in this study. How does famotidine exert its therapeutic effects on ectopic ossification in the cervical spine? Histopathology of OPLL suggests that ectopic bone formation, in particular through endochondral ossification, mediates the disease;12 13 degenerative changes in elastic fibres and cartilage formation were associated with OPLL12 and lesions had Haversian canals and marrow cavities.13 Our previous data showed that famotidine suppresses osteoblast marker gene expression in the tendon cell line TT-D6.8 H2 blockers may similarly negatively affect ectopic bone formation in spinal ligaments.

Besides Enpp1, two factors have been proposed in the pathogenesis of OPLL, based on in vivo data: runt-related transcription factor 2 (Runx2) and Indian hedgehog (Ihh). Runx2, a master regulator of osteogenesis,14 15 is expressed in OPLL, and loss of one copy of

---

**Figure 2** Change over time in ossification of the posterior longitudinal ligament (OPLL)-like ectopic ossification in individual Enpp1ttw/ ttw mice reported in figure 1. Quantitation of OPLL-like ectopic ossification for each Enpp1ttw/ ttw mouse either treated with famotidine from 4 weeks of age or controls. X-axes indicate ages of mice. Mineral cont., mineral content; Mineral dens., mineral density.
Runx2 affects OPLL-like lesions under the Enpp1^{−/−}/tw background. Fifteen weeks of age (▲: 5 male and 7 female mice at the outset) and 15 weeks of age (●: 5 male and 7 female mice at the outset) as well as controls (◆: 3 male and 8 female mice at the outset). X-axes indicate ages of mice.

Figure 3  Survival rates of famotidine-treated Enpp1^{−/−}/tw mice treated with famotidine from 4 weeks of age (●: 5 male and 8 female mice at the outset) and 15 weeks of age (▲: 5 male and 7 female mice at the outset) as well as controls (◆: 3 male and 8 female mice at the outset). X-axes indicate ages of mice.

focus on osteoclastogenesis. Although the results of our limited number of analyses suggest that such adverse effects are unlikely, further large-scale studies will be necessary to verify both the adverse and therapeutic effects on OPLL.

Author affiliations
1Department of Sensory and Motor System Medicine, The University of Tokyo Graduate School of Medicine, Tokyo, Japan
2Division of Clinical Biotechnology, The University of Tokyo Graduate School of Medicine, Tokyo, Japan
3Department of Bioengineering, The University of Tokyo Graduate School of Engineering, Tokyo, Japan

Acknowledgements The authors thank Katsue Morii, Harumi Kobayashi, Satomi Ogura, Asuka Miyoshi, Ayano Fujisawa, Yuko Kariya, Nozomi Nagumo and RATOC System Engineering Co, Ltd, for technical assistance.

Contributors KY and SO conceived the project; YM, KY, AY and HA performed the experiments; YM, KY, TT, UC and SO analysed and interpreted the data; and YM, KY, UI and SO wrote the manuscript.

Funding This work was supported by Grants-in-Aid for Scientific Research (23592159 and 24240069), the Center for Medical System Innovation, Core-to-Core Program A (Advanced Research Networks), the S-innovation Program, and the Center for NanoBio Integration.

Competing interests None declared.

Provenance and peer review Not commissioned; externally peer reviewed.

Data sharing statement Not additional data are available.

Open Access This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/

REFERENCES
1. Matsunaga S, Kukita M, Hayashi K, et al. Pathogenesis of myelopathy in patients with ossification of the posterior longitudinal ligament. J Neurosurg 2002;96(2 Suppl):168–72.
2. Matsunaga S, Sakou T. Ossification of the posterior longitudinal ligament of the cervical spine: etiology and natural history. Spine (Phila Pa 1976) 2012;37:E309–14.
3. Ikegawa S. Genetics of ossification of the posterior longitudinal ligament of the spine: a mini review. J Bone Metab 2014;21:127–32.
4. Pham MH, Attenello FJ, Lucas J, et al. Conservative management of ossification of the posterior longitudinal ligament. J Orthop Surg Res 2011;30:E2.
5. Li H, Dai LY. A systematic review of complications in cervical spine surgery for ossification of the posterior longitudinal ligament. Spine J 2011;11:1049–57.
6. Furukawa K. Pharmacological aspect of ectopic ossification in spinal ligament tissues. Pharmacol Ther 2008;118:352–8.
7. Yokoyama M, Aono H, Takeda A, et al. Cimetidine for chronic calcifying tendinitis of the shoulder. Reg Anesth Pain Med 2003;28:428–52.
8. Yamamoto K, Kojima H, Koshima I, et al. Famotidine suppresses osteogenic differentiation of tendon cells in vitro and pathological calcification of tendon in vivo. J Orthop Res 2012;30:1998–62.
9. Okawa A, Nakamura I, Goto S, et al. Mutation in NPPS in a mouse model of ossification of the posterior longitudinal ligament of the spine. Nat Genet 1998;19:271–3.
10. Nakamura I, Ikegawa S, Okawa A, et al. Association of the human NPPS gene with ossification of the posterior longitudinal ligament of the spine (OPLL). Hum Genet 1999;104:492–7.
11. Iwasaki M, Piao J, Kimura A, et al. Runx2 haploinsufficiency ameliorates the development of ossification of the posterior longitudinal ligament. PLoS ONE 2012;7:e43372.
12. Satoh R, Uchida K, Kobayashi S, et al. Ossification of the posterior longitudinal ligament of the cervical spine: histopathological findings.

Maeda Y, et al. RMD Open 2015;1:e000068. doi:10.1136/rmdopen-2015-000068
around the calcification and ossification front. J Neurosurg Spine 2007;7:174–83.
13. Yasui N, Ono K, Yamaura I, et al. Immunohistochemical localization of types I, II, and III collagens in the ossified posterior longitudinal ligament of the human cervical spine. Calcif Tissue Int 1983;35:159–63.
14. Komori T. Signaling networks in RUNX2-dependent bone development. J Cell Biochem 2011;112:750–5.
15. Komori T, Yagi H, Nomura S, et al. Targeted disruption of Cbfa1 results in a complete lack of bone formation owing to maturational arrest of osteoblasts. Cell 1997;89:755–64.
16. Sugita D, Yayama T, Uchida K, et al. Indian hedgehog signaling promotes chondrocyte differentiation in enchondral ossification in human cervical ossification of the posterior longitudinal ligament. Spine (Phila Pa 1976) 2013;38:E1388–96.
17. Long F, Chung UI, Ohba S, et al. Ihh signaling is directly required for the osteoblast lineage in the endochondral skeleton. Development 2004;131:1309–18.
18. Chung UI, Schipani E, McMahon AP, et al. Indian hedgehog couples chondrogenesis to osteogenesis in endochondral bone development. J Clin Invest 2001;107:295–304.
19. Nakajima M, Takahashi A, Tsuji T, et al. A genome-wide association study identifies susceptibility loci for ossification of the posterior longitudinal ligament of the spine. Nat Genet 2014;46:1012–16.
20. Biosse-Duplan M, Baroukh B, Dy M, et al. Histamine promotes osteoclastogenesis through the differential expression of histamine receptors on osteoclasts and osteoblasts. Am J Pathol 2009;174:1426–34.